

# Giorgio Zauli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4191716/publications.pdf>

Version: 2024-02-01

273  
papers

10,738  
citations

39113

52  
h-index

56606

87  
g-index

277  
all docs

277  
docs citations

277  
times ranked

15010  
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 nucleocapsid protein and ultrastructural modifications in small bowel of a 4-week-negative COVID-19 patient. <i>Clinical Microbiology and Infection</i> , 2021, 27, 936-937.	2.8	20
2	Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors. <i>Current Oncology</i> , 2021, 28, 2439-2451.	0.9	2
3	The Italian law on body donation: A position paper of the Italian College of Anatomists. <i>Annals of Anatomy</i> , 2021, 238, 151761.	1.0	13
4	Autoinflammatory Diseases and Cytokine Storms—Imbalances of Innate and Adaptive Immunity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11241.	1.8	14
5	TRAIL/DR5 pathway promotes AKT phosphorylation, skeletal muscle differentiation, and glucose uptake. <i>Cell Death and Disease</i> , 2021, 12, 1089.	2.7	4
6	Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients. <i>Frontiers in Pharmacology</i> , 2020, 11, 1156.	1.6	16
7	COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-Chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3474.	1.8	290
8	Sex/Gender-Specific Imbalance in CVD: Could Physical Activity Help to Improve Clinical Outcome Targeting CVD Molecular Mechanisms in Women?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1477.	1.8	24
9	TRAIL treatment prevents renal morphological changes and TGF- $\beta$ 2-induced mesenchymal transition associated with diabetic nephropathy. <i>Clinical Science</i> , 2020, 134, 2337-2352.	1.8	9
10	Maternal Haplotypes in DHFR Promoter and MTHFR Gene in Tuning Childhood Acute Lymphoblastic Leukemia Onset-Latency: Genetic/Epigenetic Mother/Child Dyad Study (GEMCDS). <i>Genes</i> , 2019, 10, 634.	1.0	10
11	TRAIL, OPC, and TWEAK in kidney disease: biomarkers or therapeutic targets?. <i>Clinical Science</i> , 2019, 133, 1145-1166.	1.8	30
12	Actively targeted nanocarriers for drug delivery to cancer cells. <i>Expert Opinion on Drug Delivery</i> , 2019, 16, 481-496.	2.4	52
13	Targeting mTOR in Acute Lymphoblastic Leukemia. <i>Cells</i> , 2019, 8, 190.	1.8	44
14	Role of physical exercise in the regulation of epigenetic mechanisms in inflammation, cancer, neurodegenerative diseases, and aging process. <i>Journal of Cellular Physiology</i> , 2019, 234, 14852-14864.	2.0	45
15	Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update. <i>Journal of Cellular Physiology</i> , 2018, 233, 6440-6454.	2.0	35
16	TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse. <i>Clinical Science</i> , 2018, 132, 69-83.	1.8	16
17	Roles and clinical implications of microRNAs in acute lymphoblastic leukemia. <i>Journal of Cellular Physiology</i> , 2018, 233, 5642-5654.	2.0	35
18	Cardiovascular disease-related miRNAs expression: potential role as biomarkers and effects of training exercise. <i>Oncotarget</i> , 2018, 9, 17238-17254.	0.8	51

#	ARTICLE	IF	CITATIONS
19	Oxidative stress: role of physical exercise and antioxidant nutraceuticals in adulthood and aging. <i>Oncotarget</i> , 2018, 9, 17181-17198.	0.8	303
20	HelixComplex snail mucus exhibits pro-survival, proliferative and pro-migration effects on mammalian fibroblasts. <i>Scientific Reports</i> , 2018, 8, 17665.	1.6	50
21	Impact of physical exercise in cancer survivors during and after antineoplastic treatments. <i>Oncotarget</i> , 2018, 9, 14005-14034.	0.8	71
22	Physical training interventions for children and teenagers affected by acute lymphoblastic leukemia and related treatment impairments. <i>Oncotarget</i> , 2018, 9, 17199-17209.	0.8	23
23	Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease. <i>PLoS ONE</i> , 2018, 13, e0203716.	1.1	14
24	TRAIL and Ceruloplasmin Inverse Correlation as a Representative Crosstalk between Inflammation and Oxidative Stress. <i>Mediators of Inflammation</i> , 2018, 2018, 1-8.	1.4	8
25	Effects of Hypoxia and Bed Rest on Markers of Cardiometabolic Risk: Compensatory Changes in Circulating TRAIL and Glutathione Redox Capacity. <i>Frontiers in Physiology</i> , 2018, 9, 1000.	1.3	11
26	Gene-gene interactions among coding genes of iron-homeostasis proteins and APOE-alleles in cognitive impairment diseases. <i>PLoS ONE</i> , 2018, 13, e0193867.	1.1	40
27	Influence of physical exercise on microRNAs in skeletal muscle regeneration, aging and diseases. <i>Oncotarget</i> , 2018, 9, 17220-17237.	0.8	42
28	Association between thyroid hormones and TRAIL. <i>Clinical Biochemistry</i> , 2017, 50, 972-976.	0.8	2
29	Inflammation and Cardiovascular Cross Talk in Ischemic Vascular Diseases. <i>Mediators of Inflammation</i> , 2017, 2017, 1-2.	1.4	3
30	Low Circulating TRAIL Levels Are Associated with Increase of Resistin and Lipocalin-2/ngal Adipokines in Postmenopausal Women. <i>Mediators of Inflammation</i> , 2017, 2017, 1-8.	1.4	6
31	MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 133.	6.9	213
32	The Î³-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells. <i>Oncotarget</i> , 2017, 8, 59235-59245.	0.8	19
33	PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. <i>Oncotarget</i> , 2017, 8, 23213-23227.	0.8	15
34	Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 70623-70638.	0.8	21
35	Multimodal near-infrared-emitting PluS Silica nanoparticles with fluorescent, photoacoustic, and photothermal capabilities. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 4865-4874.	3.3	23
36	Clinical perspectives of TRAIL: insights into central nervous system disorders. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 2017-2027.	2.4	36

#	ARTICLE	IF	CITATIONS
37	Circulating levels of TNF-related apoptosis inducing-ligand are decreased in patients with large adult-type granulosa cell tumorsâ€”implications for therapeutic potential. <i>Tumor Biology</i> , 2016, 37, 11909-11916.	0.8	3
38	Redox signaling and oxidative stress: Cross talk with TNF-related apoptosis inducing ligand activity. <i>International Journal of Biochemistry and Cell Biology</i> , 2016, 81, 364-374.	1.2	34
39	Serum Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Levels in Older Subjects with Dementia and Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2016, 41, 273-280.	0.7	11
40	Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 147-156.	2.9	22
41	Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016, 7, 55690-55703.	0.8	14
42	Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. <i>Oncotarget</i> , 2016, 7, 79842-79853.	0.8	22
43	Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1. <i>Oncotarget</i> , 2016, 7, 18965-18977.	0.8	25
44	Two-gene mutation in a single patient: Biochemical and functional analysis for a correct interpretation of exome results. <i>Molecular Medicine Reports</i> , 2015, 12, 6128-6132.	1.1	2
45	Kinetic Profiles of Inflammatory Mediators in the Conjunctival Sac Fluid of Patients upon Photorefractive Keratectomy. <i>Mediators of Inflammation</i> , 2015, 2015, 1-7.	1.4	2
46	TNF-Related Apoptosis Inducing Ligand in Ocular Cancers and Ocular Diabetic Complications. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	5
47	TRAIL Modulates the Immune System and Protects against the Development of Diabetes. <i>Journal of Immunology Research</i> , 2015, 2015, 1-12.	0.9	35
48	Applications of nanoparticles in cancer medicine and beyond: optical and multimodal in vivo imaging, tissue targeting and drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 1837-1849.	2.4	44
49	Serum TRAIL levels increase shortly after insulin therapy and metabolic stabilization in children with type 1 diabetes mellitus. <i>Acta Diabetologica</i> , 2015, 52, 1003-1006.	1.2	7
50	The anti-leukemic activity of sodium dichloroacetate in p53mutated/null cells is mediated by a p53-independent ILF3/p21 pathway. <i>Oncotarget</i> , 2015, 6, 2385-2396.	0.8	16
51	Heterogeneity of mesenchymal stromal cells in lymphoproliferative disorders. <i>Frontiers in Bioscience - Landmark</i> , 2014, 19, 139.	3.0	3
52	Soluble TRAIL is present at high concentrations in seminal plasma and promotes spermatozoa survival. <i>Reproduction</i> , 2014, 148, 191-198.	1.1	7
53	The First Trimester Gravid Serum Regulates Procalcitonin Expression in Human Macrophages Skewing Their Phenotype In Vitro. <i>Mediators of Inflammation</i> , 2014, 2014, 1-10.	1.4	14
54	In Vitro Endothelial Cell Proliferation Assay Reveals Distinct Levels of Proangiogenic Cytokines Characterizing Sera of Healthy Subjects and of Patients with Heart Failure. <i>Mediators of Inflammation</i> , 2014, 2014, 1-11.	1.4	12

#	ARTICLE	IF	CITATIONS
55	Association of Serum Tumor Necrosis Factor-Related Apoptosis Inducing Ligand with Body Fat Distribution as Assessed by Dual X-Rays Absorptiometry. <i>Mediators of Inflammation</i> , 2014, 2014, 1-6.	1.4	1
56	Intranasal Administration of Recombinant TRAIL Down-Regulates CXCL-1/KC in an Ovalbumin-Induced Airway Inflammation Murine Model. <i>PLoS ONE</i> , 2014, 9, e115387.	1.1	15
57	Selective induction of TP53/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3. <i>Molecular Carcinogenesis</i> , 2014, 53, 498-504.	1.3	11
58	Modulation of Circulating Cytokine-Chemokine Profile in Patients Affected by Chronic Venous Insufficiency Undergoing Surgical Hemodynamic Correction. <i>Journal of Immunology Research</i> , 2014, 2014, 1-10.	0.9	24
59	NF- $\kappa$ B pathways in hematological malignancies. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 2083-2102.	2.4	140
60	Circulating levels of TNF-related apoptosis inducing ligand (TRAIL). <i>Clinical Endocrinology</i> , 2014, 80, 182-183.	1.2	2
61	The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement. <i>Acta Diabetologica</i> , 2014, 51, 239-246.	1.2	25
62	Inverse Correlation Between Circulating Levels of TNF-Related Apoptosis-Inducing Ligand and 17 $\beta$ -Estradiol. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E659-E664.	1.8	14
63	Multiple dye-doped NIR-emitting silica nanoparticles for both flow cytometry and in vivo imaging. <i>RSC Advances</i> , 2014, 4, 18278-18285.	1.7	18
64	Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. <i>Molecular and Cellular Endocrinology</i> , 2014, 394, 13-20.	1.6	48
65	Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3. <i>Oncotarget</i> , 2014, 5, 4347-4360.	0.8	22
66	The p53 transcriptional pathway is preserved in ATM mutated and NOTCH1 mutated chronic lymphocytic leukemias. <i>Oncotarget</i> , 2014, 5, 12635-12645.	0.8	9
67	Human Colostrum and Breast Milk Contain High Levels of TNF-Related Apoptosis-Inducing Ligand (TRAIL). <i>Journal of Human Lactation</i> , 2013, 29, 23-25.	0.8	10
68	Proper design of silica nanoparticles combines high brightness, lack of cytotoxicity and efficient cell endocytosis. <i>Nanoscale</i> , 2013, 5, 7897.	2.8	47
69	The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus and increases serum level of IL-12p40. <i>Acta Diabetologica</i> , 2013, 50, 899-906.	1.2	20
70	C-Reactive Protein Downregulates TRAIL Expression in Human Peripheral Monocytes via an Egr-1-Dependent Pathway. <i>Clinical Cancer Research</i> , 2013, 19, 1949-1959.	3.2	36
71	Patients affected by metabolic syndrome show decreased levels of circulating platelet derived growth factor (PDGF)-BB. <i>Clinical Nutrition</i> , 2013, 32, 259-264.	2.3	24
72	Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1. <i>Investigational New Drugs</i> , 2013, 31, 780-786.	1.2	2

#	ARTICLE	IF	CITATIONS
73	Lovastatin Dose-Dependently Potentiates the Pro-inflammatory Activity of Lipopolysaccharide Both In Vitro and In Vivo. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 981-988.	1.1	12
74	The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells. <i>Investigational New Drugs</i> , 2013, 31, 458-460.	1.2	4
75	The circulating levels of TRAIL are extremely low after delivery but rapidly recover in both mothers and newborns. <i>Cytokine</i> , 2013, 64, 51-53.	1.4	2
76	Human papillomavirus infection is associated with decreased levels of GM-CSF in cervico-vaginal fluid of infected women. <i>Journal of Clinical Virology</i> , 2013, 58, 479-481.	1.6	19
77	Endothelial PDGF-BB produced ex vivo correlates with relevant hemodynamic parameters in patients affected by chronic venous disease. <i>Cytokine</i> , 2013, 63, 92-96.	1.4	24
78	Presence of CTAK/CCL27, MCP-3/CCL7 and LIF in human colostrum and breast milk. <i>Cytokine</i> , 2013, 61, 26-28.	1.4	12
79	Release of a specific set of proinflammatory adipokines by differentiating 3T3-L1 cells. <i>Nutrition</i> , 2013, 29, 332-337.	1.1	10
80	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. <i>Journal of Hematology and Oncology</i> , 2013, 6, 83.	6.9	14
81	GM-CSF Exhibits Anti-Inflammatory Activity on Endothelial Cells Derived from Chronic Venous Disease Patients. <i>Mediators of Inflammation</i> , 2013, 2013, 1-9.	1.4	11
82	Levels of TNF-Related Apoptosis-Inducing Ligand (TRAIL) Show a Long-term Stability in the Breast Milk of Mothers of Preterm Infants. <i>Journal of Human Lactation</i> , 2013, 29, 350-353.	0.8	7
83	Inhibitory Effect of Natural Anti-Inflammatory Compounds on Cytokines Released by Chronic Venous Disease Patient-Derived Endothelial Cells. <i>Mediators of Inflammation</i> , 2013, 2013, 1-13.	1.4	18
84	Cytokine Levels in the Serum of Healthy Subjects. <i>Mediators of Inflammation</i> , 2013, 2013, 1-6.	1.4	271
85	Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts. <i>Clinical Cancer Research</i> , 2013, 19, 3871-3880.	3.2	30
86	<i>ARHGDI1</i> , a mutant <i>TP53</i> -associated Rho GTPase dissociation inhibitor, is overexpressed in gene expression profiles of <i>TP53</i> -disrupted chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2013, 161, 596-599.	1.2	3
87	Association of Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) with Central Adiposity and Low-Density Lipoprotein Cholesterol. <i>PLoS ONE</i> , 2013, 8, e58225.	1.1	21
88	In Vitro Characterization of Circulating Endothelial Progenitor Cells Isolated from Patients with Acute Coronary Syndrome. <i>PLoS ONE</i> , 2013, 8, e56377.	1.1	29
89	TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases. <i>Current Drug Targets</i> , 2012, 13, 1089-1095.	1.0	8
90	Cell-Based Therapies for Diabetic Complications. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-10.	3.8	39

#	ARTICLE	IF	CITATIONS
91	TRAIL, a New Weapon against Neointimal Hyperplasia. <i>Cardiology</i> , 2012, 123, 94-96.	0.6	5
92	Soluble TRAIL is elevated in recurrent miscarriage and inhibits the in vitro adhesion and migration of HTR8 trophoblastic cells. <i>Human Reproduction</i> , 2012, 27, 2941-2947.	0.4	30
93	Editorial [Innovative Therapeutic Approaches for the Treatment of Pediatric Autoimmune and Inflammatory Diseases Executive (Guest Editor: Giorgio Zauli)]. <i>Current Pharmaceutical Design</i> , 2012, 18, 5728-5728.	0.9	0
94	State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2012, 7, 207-217.	0.8	31
95	Potential Role of TRAIL in the Management of Autoimmune Diabetes Mellitus. <i>Current Pharmaceutical Design</i> , 2012, 18, 5759-5765.	0.9	10
96	The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. <i>Haematologica</i> , 2012, 97, 1722-1730.	1.7	44
97	SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155. <i>Investigational New Drugs</i> , 2012, 30, 2403-2406.	1.2	14
98	The energy balance positively regulates the levels of circulating TNF-related apoptosis inducing ligand in humans. <i>Clinical Nutrition</i> , 2012, 31, 1018-1021.	2.3	11
99	The MDM2 inhibitor Nutlin-3 modulates dendritic cell-induced T cell proliferation. <i>Human Immunology</i> , 2012, 73, 342-345.	1.2	28
100	Merkel-cell polyomavirus (MCPyV) is rarely associated to B-chronic lymphocytic leukemia (1 out of 50) samples and occurs late in the natural history of the disease. <i>Journal of Clinical Virology</i> , 2012, 55, 367-369.	1.6	14
101	TRAIL administration down-modulated the acute systemic inflammatory response induced in a mouse model by muramyl dipeptide or lipopolysaccharide. <i>Cytokine</i> , 2012, 60, 43-46.	1.4	12
102	Simultaneous determination of multiple cytokines reveals a pro-inflammatory and pro-angiogenic signature after major cardiothoracic surgery: Potential role of C-reactive protein. <i>Cytokine</i> , 2012, 60, 593-595.	1.4	1
103	JCV+ Patients with Inflammatory Bowel Disease show elevated plasma levels of MIG and SCF. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1194-1196.	0.9	5
104	TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. <i>Clinical Science</i> , 2012, 123, 547-555.	1.8	44
105	Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells. <i>Investigational New Drugs</i> , 2012, 30, 1731-1735.	1.2	6
106	<sc>MCL</sc>1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor <sc>S</sc>orafenib with respect to <sc>D</sc>asatinib. <i>British Journal of Haematology</i> , 2012, 157, 510-514.	1.2	7
107	Activation of the p53 pathway induces $\beta$ -smooth muscle actin expression in both myeloid leukemic cells and normal macrophages. <i>Journal of Cellular Physiology</i> , 2012, 227, 1829-1837.	2.0	12
108	In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody. <i>Investigational New Drugs</i> , 2012, 30, 405-407.	1.2	3

#	ARTICLE	IF	CITATIONS
109	Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts. <i>Investigational New Drugs</i> , 2012, 30, 803-807.	1.2	4
110	The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL. <i>Investigational New Drugs</i> , 2012, 30, 810-818.	1.2	1
111	Endothelial Cells Obtained from Patients Affected by Chronic Venous Disease Exhibit a Pro-Inflammatory Phenotype. <i>PLoS ONE</i> , 2012, 7, e39543.	1.1	42
112	TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases. <i>Current Drug Targets</i> , 2012, 13, 1215-1221.	1.0	13
113	Molecular targets for selective killing of TRAIL-resistant leukemic cells. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 931-942.	1.5	5
114	Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. <i>Molecular and Cellular Endocrinology</i> , 2011, 331, 136-142.	1.6	34
115	Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. <i>Atherosclerosis</i> , 2011, 215, 452-458.	0.4	90
116	Osteoprotegerin promotes vascular fibrosis via a TGF- $\beta$ 1 autocrine loop. <i>Atherosclerosis</i> , 2011, 218, 61-68.	0.4	51
117	Circulating TRAIL Shows a Significant Post-Partum Decline Associated to Stressful Conditions. <i>PLoS ONE</i> , 2011, 6, e27011.	1.1	6
118	Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines. <i>Investigational New Drugs</i> , 2011, 29, 392-395.	1.2	11
119	Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells. <i>Journal of Cellular Physiology</i> , 2011, 226, 2279-2286.	2.0	12
120	Recent Advances in the Therapeutic Perspectives of Nutlin-3. <i>Current Pharmaceutical Design</i> , 2011, 17, 569-577.	0.9	150
121	Nutlin-3 Downregulates the Expression of the Oncogene <i>TCL1</i> in Primary B Chronic Lymphocytic Leukemic Cells. <i>Clinical Cancer Research</i> , 2011, 17, 5649-5655.	3.2	17
122	Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53 wild-type and p53 mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway. <i>Clinical Cancer Research</i> , 2011, 17, 762-770.	3.2	48
123	miR-34a Induces the Downregulation of Both <i>E2F1</i> and <i>B-Myb</i> Oncogenes in Leukemic Cells. <i>Clinical Cancer Research</i> , 2011, 17, 2712-2724.	3.2	69
124	microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. <i>Blood</i> , 2010, 116, 945-952.	0.6	200
125	TNF- $\alpha$ modulates the migratory response of mesenchymal stem cells to TRAIL. <i>Cellular and Molecular Life Sciences</i> , 2010, 67, 1307-1314.	2.4	19
126	Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL). <i>Journal of Cellular Physiology</i> , 2010, 222, 357-364.	2.0	10



#	ARTICLE	IF	CITATIONS
127	Perifosine plus nutlin-3 combination shows a synergistic anti-leukaemic activity. <i>British Journal of Haematology</i> , 2010, 148, 957-961.	1.2	11
128	<i>p53</i> is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of CLL with a poor cytotoxic response to Nutlin-3. <i>British Journal of Haematology</i> , 2010, 150, 237-239.	1.2	27
129	Treatment With Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Alleviates the Severity of Streptozotocin-Induced Diabetes. <i>Diabetes</i> , 2010, 59, 1261-1265.	0.3	58
130	The tumour necrosis factor-related apoptosis-inducing ligand-osteoprotegerin system in limited systemic sclerosis: a new disease marker?. <i>Rheumatology</i> , 2010, 49, 1173-1176.	0.9	9
131	Circulating levels of frizzled-related protein (FRZB) are increased in patients with early rheumatoid arthritis and decrease in response to disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1733-1734.	0.5	6
132	The Oncogene DEK Promotes Leukemic Cell Survival and Is Downregulated by both Nutlin-3 and Chlorambucil in B-Chronic Lymphocytic Leukemic Cells. <i>Clinical Cancer Research</i> , 2010, 16, 1824-1833.	3.2	23
133	An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. <i>Atherosclerosis</i> , 2010, 210, 274-277.	0.4	61
134	Metalloproteinase 2 cleaves in vitro recombinant TRAIL: Potential implications for the decreased serum levels of TRAIL after acute myocardial infarction. <i>Atherosclerosis</i> , 2010, 211, 333-336.	0.4	30
135	Human Bone Marrow Mesenchymal Stem Cells Display Anti-Cancer Activity in SCID Mice Bearing Disseminated Non-Hodgkin's Lymphoma Xenografts. <i>PLoS ONE</i> , 2010, 5, e11140.	1.1	128
136	Potential Prognostic Significance of Decreased Serum Levels of TRAIL after Acute Myocardial Infarction. <i>PLoS ONE</i> , 2009, 4, e4442.	1.1	82
137	Conjunctival sac fluid contains elevated levels of soluble TRAIL: Implications for the anti-tumoral surveillance of the anterior surface of the eye. <i>Journal of Cellular Physiology</i> , 2009, 218, 199-204.	2.0	11
138	Role of full-length osteoprotegerin in tumor cell biology. <i>Cellular and Molecular Life Sciences</i> , 2009, 66, 841-851.	2.4	70
139	Reduced expression of cell cycle-associated genes in B lymphocytes purified from the peripheral blood of early-stage B chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2009, 145, 424-426.	1.2	2
140	Unsung Hero Robert C. Gallo. <i>Science</i> , 2009, 323, 206-207.	6.0	2
141	Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. <i>Blood</i> , 2009, 113, 4300-4308.	0.6	83
142	B-Cell Chronic Lymphocytic Leukemia Cells Exposed to the Non-Genotoxic p53 Activator Nutlin-3 Are Characterized by a Specific Gene Expression Signature.. <i>Blood</i> , 2009, 114, 4374-4374.	0.6	0
143	TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27 <sup>Kip1</sup> accumulation in pre-osteoclast precursors. <i>Journal of Cellular Physiology</i> , 2008, 214, 117-125.	2.0	61
144	Potential involvement of TRAIL in Treg cell-mediated osteoclast suppression: Comment on the article by Zaiss et al. <i>Arthritis and Rheumatism</i> , 2008, 58, 1887-1887.	6.7	0

#	ARTICLE	IF	CITATIONS
145	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Promotes Migration of Human Bone Marrow Multipotent Stromal Cells. <i>Stem Cells</i> , 2008, 26, 2955-2963.	1.4	56
146	Soluble TRAIL does not impair the anti-osteoclastic activity of osteoprotegerin. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 1063-1065.	1.6	6
147	Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells. <i>Journal of Leukocyte Biology</i> , 2008, 83, 434-437.	1.5	14
148	The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis. <i>Rheumatology</i> , 2008, 48, 293-298.	0.9	29
149	Letter by Secchiero and Zauli Regarding Article, "Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in LDLr <sup>-/-</sup> Mice", <i>Circulation</i> , 2008, 118, e18; author reply e19.	1.6	5
150	The Puzzling Role of TRAIL in Endothelial Cell Biology. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, e4; author reply e5-6.	1.1	11
151	Role of TRAIL in osteoclastogenesis. <i>Blood</i> , 2008, 111, 5413-5413.	0.6	3
152	Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells. <i>Blood</i> , 2008, 111, 1287-1294.	0.6	30
153	The MDM2 Inhibitor Nutlins as an Innovative Therapeutic Tool for the Treatment of Haematological Malignancies. <i>Current Pharmaceutical Design</i> , 2008, 14, 2100-2110.	0.9	85
154	Tumor necrosis factor-related apoptosis-inducing ligand and the regulation of hematopoiesis. <i>Current Opinion in Hematology</i> , 2008, 15, 42-48.	1.2	66
155	Editorial [Hot Topic: Innovative Therapeutical Approaches for Hematological Malignancies Based on Molecular Targeted Therapies (Executive Editor: Giorgio Zauli) ]. <i>Current Pharmaceutical Design</i> , 2008, 14, 2022-2022.	0.9	2
156	Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3. <i>Circulation Research</i> , 2007, 100, 61-69.	2.0	124
157	Synergistic Cytotoxic Activity of Recombinant TRAIL Plus the Non-Genotoxic Activator of the p53 Pathway Nutlin-3 in Acute Myeloid Leukemia Cells. <i>Current Drug Metabolism</i> , 2007, 8, 395-403.	0.7	69
158	Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. <i>Blood</i> , 2007, 110, 536-543.	0.6	121
159	The MDM-2 Antagonist Nutlin-3 Promotes the Maturation of Acute Myeloid Leukemic Blasts. <i>Neoplasia</i> , 2007, 9, 853-861.	2.3	41
160	Insulin down-regulates TRAIL expression in vascular smooth muscle cells both in vivo and in vitro. <i>Journal of Cellular Physiology</i> , 2007, 212, 89-95.	2.0	22
161	Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70. <i>Journal of Cellular Physiology</i> , 2007, 213, 229-236.	2.0	11
162	MDM2 Antagonist Nutlin-3 Suppresses the Proliferation and Differentiation of Human Pre-Osteoclasts Through a p53-Dependent Pathway. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 1621-1630.	3.1	22

#	ARTICLE	IF	CITATIONS
163	An Increased Osteoprotegerin Serum Release Characterizes the Early Onset of Diabetes Mellitus and May Contribute to Endothelial Cell Dysfunction. <i>American Journal of Pathology</i> , 2006, 169, 2236-2244.	1.9	129
164	The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. <i>Cytokine and Growth Factor Reviews</i> , 2006, 17, 245-257.	3.2	120
165	Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). <i>Blood</i> , 2006, 107, 4122-4129.	0.6	156
166	Morphological features of osteoclasts derived from a co-culture system. <i>Journal of Molecular Histology</i> , 2006, 37, 171-177.	1.0	17
167	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) regulates endothelial nitric oxide synthase (eNOS) activity and its localization within the human vein endothelial cells (HUVEC) in culture. <i>Journal of Cellular Biochemistry</i> , 2006, 97, 782-794.	1.2	32
168	Involvement of TRAIL/TRAIL-receptors in human intestinal cell differentiation. <i>Journal of Cellular Physiology</i> , 2006, 206, 647-654.	2.0	35
169	Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells. <i>Journal of Cellular Physiology</i> , 2006, 207, 158-164.	2.0	33
170	Systemic Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Delivery Shows Antiatherosclerotic Activity in Apolipoprotein E-Null Diabetic Mice. <i>Circulation</i> , 2006, 114, 1522-1530.	1.6	147
171	TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. <i>Blood</i> , 2005, 105, 3413-3419.	0.6	98
172	The long and winding road may be getting shorter. <i>Blood</i> , 2005, 105, 4160-4160.	0.6	0
173	PI-3K/Akt and NF- $\kappa$ B pathways are activated in Jurkat T cells in response to TRAIL treatment. <i>Journal of Cellular Physiology</i> , 2005, 202, 900-911.	2.0	65
174	HIV-1 Tat protein concomitantly down-regulates apical caspase-10 and up-regulates c-FLIP in lymphoid T cells: A potential molecular mechanism to escape TRAIL cytotoxicity. <i>Journal of Cellular Physiology</i> , 2005, 203, 547-556.	2.0	54
175	Functional expression of TRAIL and TRAIL-R2 during human megakaryocytic development. <i>Journal of Cellular Physiology</i> , 2005, 204, 975-982.	2.0	25
176	Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. <i>Journal of Cellular Physiology</i> , 2005, 205, 246-252.	2.0	26
177	Different levels of the neuronal nitric oxide synthase isoform modulate the rate of osteoclastic differentiation of TIB-71 and CRL-2278 RAW 264.7 murine cell clones. <i>The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology</i> , 2005, 286A, 945-954.	2.0	14
178	Potential Pathogenetic Implications of Cyclooxygenase-2 Overexpression in B Chronic Lymphoid Leukemia Cells. <i>American Journal of Pathology</i> , 2005, 167, 1599-1607.	1.9	43
179	Evidence for a Role of TNF-Related Apoptosis-Inducing Ligand (TRAIL) in the Anemia of Myelodysplastic Syndromes. <i>American Journal of Pathology</i> , 2005, 166, 557-563.	1.9	89
180	TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Potential Candidate for Combined Treatment of Hematological Malignancies. <i>Current Pharmaceutical Design</i> , 2004, 10, 3673-3681.	0.9	43

#	ARTICLE	IF	CITATIONS
181	Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. <i>Blood</i> , 2004, 104, 2418-2424.	0.6	422
182	Modulation of the expression and activity of cyclooxygenases in normal and accelerated erythropoiesis. <i>Experimental Hematology</i> , 2004, 32, 925-934.	0.2	13
183	Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. <i>Journal of Neurochemistry</i> , 2004, 86, 126-135.	2.1	67
184	Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. <i>Journal of Cellular Physiology</i> , 2004, 201, 331-340.	2.0	117
185	Evidence for a Proangiogenic Activity of TNF-Related Apoptosis-Inducing Ligand. <i>Neoplasia</i> , 2004, 6, 364-373.	2.3	55
186	TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. <i>Blood</i> , 2004, 103, 517-522.	0.6	110
187	TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. <i>Blood</i> , 2004, 104, 2044-2050.	0.6	99
188	TRAIL Activates a Caspase 9/7-Dependent Pathway in Caspase 8/10-Defective SK-N-SH Neuroblastoma Cells with Two Functional End Points: Induction of Apoptosis and PGE2 Release. <i>Neoplasia</i> , 2003, 5, 457-466.	2.3	11
189	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Sequentially Upregulates Nitric Oxide and Prostanoid Production in Primary Human Endothelial Cells. <i>Circulation Research</i> , 2003, 92, 732-740.	2.0	119
190	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF- $\alpha$ promote the NF- $\kappa$ B-dependent maturation of normal and leukemic myeloid cells. <i>Journal of Leukocyte Biology</i> , 2003, 74, 223-232.	1.5	27
191	TRAIL Promotes the Survival and Proliferation of Primary Human Vascular Endothelial Cells by Activating the Akt and ERK Pathways. <i>Circulation</i> , 2003, 107, 2250-2256.	1.6	283
192	Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 7634-7639.	3.3	295
193	Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. <i>Blood</i> , 2002, 100, 2421-2429.	0.6	83
194	Differentially expressed genes in HIV-1 tat-expressing CD4+ T-cell line. <i>Virus Research</i> , 2002, 90, 337-345.	1.1	26
195	Role of CREB transcription factor in c-fos activation in natural killer cells. <i>European Journal of Immunology</i> , 2002, 32, 3358-3365.	1.6	1
196	Role of CREB transcription factor in c-fos activation in natural killer cells. , 2002, 32, 3358.		2
197	Tumor necrosis factor alpha (TNF-alpha) activates Jak1/Stat3-Stat5B signaling through TNFR-1 in human B cells. <i>Cell Growth &amp; Differentiation: the Molecular Biology Journal of the American Association for Cancer Research</i> , 2002, 13, 13-8.	0.8	48
198	TNF-related apoptosis-inducing ligand (TRAIL) up-regulates cyclooxygenase (COX)-1 activity and PGE(2) production in cells of the myeloid lineage. <i>Journal of Leukocyte Biology</i> , 2002, 72, 986-94.	1.5	14

#	ARTICLE	IF	CITATIONS
199	Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor $\alpha$ -related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1. <i>Blood</i> , 2001, 97, 2596-2603.	0.6	93
200	Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor $\alpha$ -related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies. <i>Blood</i> , 2001, 98, 2220-2228.	0.6	69
201	Human herpesvirus 7 induces the functional up-regulation of tumor necrosis factor $\alpha$ -related apoptosis-inducing ligand (TRAIL) coupled to TRAIL-R1 down-modulation in CD4+ T cells. <i>Blood</i> , 2001, 98, 2474-2481.	0.6	31
202	Extracellular Tat activates c-fos promoter in low serum-starved CD4+ T cells. <i>British Journal of Haematology</i> , 2001, 112, 663-670.	1.2	11
203	Comparison between different laboratory tests for the detection and prevention of heparin-induced thrombocytopenia. <i>Cytometry</i> , 2001, 46, 290-295.	1.8	29
204	HIV-1 Tat Protects CD4+ Jurkat T Lymphoblastoid Cells from Apoptosis Mediated by TNF-Related Apoptosis-Inducing Ligand. <i>Cellular Immunology</i> , 2001, 207, 89-99.	1.4	31
205	Involvement of the pathway phosphatidylinositol-3-kinase/AKT-1 in the establishment of the survival response to ionizing radiation. <i>Cellular Signalling</i> , 2001, 13, 369-375.	1.7	40
206	Interleukin $\alpha$ 2 activates nuclear phospholipase $\alpha$ 2 by mitogen-activated protein kinase-dependent phosphorylation in human natural killer cells. <i>FASEB Journal</i> , 2001, 15, 1789-1791.	0.2	37
207	HIV $\alpha$ 1 Tat protein down-regulates CREB transcription factor expression in PC12 neuronal cells through a phosphatidylinositol 3-kinase/AKT/cyclic nucleoside phosphodiesterase pathway. <i>FASEB Journal</i> , 2001, 15, 483-491.	0.2	37
208	Engagement of CD28 Modulates CXC Chemokine Receptor 4 Surface Expression in Both Resting and CD3-Stimulated CD4+ T Cells. <i>Journal of Immunology</i> , 2000, 164, 4018-4024.	0.4	25
209	Ultrastructural characterization of maturation, platelet release, and senescence of human cultured megakaryocytes. , 2000, 258, 90-99.		52
210	Differential production of IFN- $\gamma$ , analyzed at the single-cell level, by specific subsets of human NK and T cells from healthy and HIV+ subjects. , 2000, 39, 189-194.		22
211	Differential effects of stromal derived factor-1 $\gamma$ (SDF-1 $\gamma$ ) on early and late stages of human megakaryocytic development. <i>The Anatomical Record</i> , 2000, 260, 141-147.	2.3	23
212	Stroma-derived factor 1 $\alpha$ induces a selective inhibition of human erythroid development via the functional upregulation of Fas/CD95 ligand. <i>British Journal of Haematology</i> , 2000, 111, 432-440.	1.2	0
213	Infection of CD34+ hematopoietic progenitor cells by human herpesvirus 7 (HHV-7). <i>Blood</i> , 2000, 96, 126-131.	0.6	39
214	Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat-mediated CD4+ T cell hyperactivation and HIV type 1 replication. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 14620-14625.	3.3	25
215	HIV-1 Tat-mediated Inhibition of the Tyrosine Hydroxylase Gene Expression in Dopaminergic Neuronal Cells. <i>Journal of Biological Chemistry</i> , 2000, 275, 4159-4165.	1.6	77
216	Stroma-derived factor 1 $\alpha$ induces a selective inhibition of human erythroid development via the functional upregulation of Fas/CD95 ligand. <i>British Journal of Haematology</i> , 2000, 111, 432-440.	1.2	20

#	ARTICLE	IF	CITATIONS
217	Stromal derived factor-1 $\pm$ induces apoptosis in activated primary CD4+ T cells. <i>Aids</i> , 2000, 14, 748-750.	1.0	10
218	Extracellular HIV-1 Tat protein activates the transcriptional repressor inducible cAMP early repressor in both the Jurkat cell line and primary peripheral blood mononuclear cells. <i>Aids</i> , 2000, 14, 1059.	1.0	2
219	Extracellular HIV-1 Tat protein differentially activates the JNK and ERK/MAPK pathways in CD4 T cells. <i>Aids</i> , 1999, 13, 1637-1645.	1.0	50
220	Mouse peritoneal cells as a reservoir of late dendritic cell progenitors. <i>British Journal of Haematology</i> , 1999, 104, 111-118.	1.2	39
221	HIV-1 gp120 induces the activation of both c-fos and c-jun immediate-early genes in HEL megakaryocytic cells. <i>British Journal of Haematology</i> , 1999, 104, 81-86.	1.2	11
222	Selective modulation of the cyclin B/CDK1 and cyclin D/CDK4 complexes during in vitro human megakaryocyte development. <i>British Journal of Haematology</i> , 1999, 104, 820-828.	1.2	19
223	Lineage-related susceptibility of human hemopoietic cell lines to apoptosis. , 1999, 254, 1-6.		13
224	Selective modulation of specific protein kinase C (PKC) isoforms in primary human megakaryocytic vs. erythroid cells. , 1999, 255, 7-14.		12
225	All-trans retinoic acid at low concentration directly stimulates normal adult megakaryocytopoiesis in the presence of thrombopoietin or combined cytokines. <i>European Journal of Haematology</i> , 1999, 63, 149-153.	1.1	14
226	Flow cytometric quantification of HIV-1 Tat protein in tat-transfected Jurkat T cell lines. <i>Journal of Immunological Methods</i> , 1998, 221, 107-117.	0.6	2
227	Kinetics of in vitro natural killer activity against K562 cells as detected by flow cytometry. , 1998, 32, 280-285.		29
228	Enforced expression of human bcl-2 in CD4+ T cells enhances human herpesvirus 7 replication and induction of cytopathic effects. <i>European Journal of Immunology</i> , 1998, 28, 1587-1596.	1.6	5
229	Accumulation of catalytically active PKC- $\delta$ into the nucleus of HL-60 cell line plays a key role in the induction of granulocytic differentiation mediated by all-transretinoic acid. <i>British Journal of Haematology</i> , 1998, 100, 541-549.	1.2	29
230	Human herpesvirus type 7 in Hodgkin's disease. <i>British Journal of Haematology</i> , 1998, 101, 492-499.	1.2	27
231	Extracellular HIV-1 Tat Protein Induces a Rapid and Selective Activation of Protein Kinase C (PKC)- $\delta$ , $\mu$ , and $\eta$ Isoforms in PC12 Cells. <i>Biochemical and Biophysical Research Communications</i> , 1998, 242, 332-337.	1.0	35
232	Characterization of the Effects of Two Polysulfonated Distamycin A Derivatives, PNU145156E and PNU153429, on HIV Type 1 Tat Protein. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 1561-1571.	0.5	16
233	Impaired telomerase activity in uninfected haematopoietic progenitors in HIV-1-infected patients. <i>Aids</i> , 1998, 12, 999-1005.	1.0	36
234	HIV-1 Tat induces tyrosine phosphorylation of p125FAK and its association with phosphoinositide 3-kinase in PC12 cells. <i>Aids</i> , 1998, 12, 1275-1284.	1.0	26

#	ARTICLE	IF	CITATIONS
235	Progressive and Persistent Downregulation of Surface CXCR4 in CD4+ T Cells Infected With Human Herpesvirus 7. <i>Blood</i> , 1998, 92, 4521-4528.	0.6	28
236	Human Herpesvirus 7 Infection Induces Profound Cell Cycle Perturbations Coupled to Disregulation of cdc2 and Cyclin B and Polyploidization of CD4+ T Cells. <i>Blood</i> , 1998, 92, 1685-1696.	0.6	29
237	The Induction of Megakaryocyte Differentiation Is Accompanied by Selective Ser133 Phosphorylation of the Transcription Factor CREB in Both HEL Cell Line and Primary CD34+Cells. <i>Blood</i> , 1998, 92, 472-480.	0.6	28
238	The Induction of Megakaryocyte Differentiation Is Accompanied by Selective Ser133 Phosphorylation of the Transcription Factor CREB in Both HEL Cell Line and Primary CD34+Cells. <i>Blood</i> , 1998, 92, 472-480.	0.6	4
239	In Vitro Senescence and Apoptotic Cell Death of Human Megakaryocytes. <i>Blood</i> , 1997, 90, 2234-2243.	0.6	133
240	Thrombopoietin Enhances the $\beta$ 2-Integrin-Dependent Adhesion of Megakaryocytic Cells to Fibrinogen or Fibronectin Through PI 3 Kinase. <i>Blood</i> , 1997, 89, 883-895.	0.6	70
241	Upregulation of c-Fos in Activated T Lymphoid and Monocytic Cells by Human Immunodeficiency Virus-1 Tat Protein. <i>Blood</i> , 1997, 89, 1654-1664.	0.6	23
242	Selective enrichment in human megakaryocyte progenitors by the B203.13 surface differentiation antigen. <i>British Journal of Haematology</i> , 1997, 99, 766-769.	1.2	0
243	The engagement of CD4 surface antigen in the HEL haemopoietic cell line upregulates the transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1) promoter activity. <i>British Journal of Haematology</i> , 1997, 97, 571-578.	1.2	3
244	Extracellular HIV-1 Tat protein activates phosphatidylinositol 3- and Akt/PKB kinases in CD4+ T lymphoblastoid Jurkat cells. <i>European Journal of Immunology</i> , 1997, 27, 2805-2811.	1.6	78
245	IMP dehydrogenase inhibitor, tiazofurin, induces apoptosis in K562 human erythroleukemia cells. , 1997, 30, 61-66.		51
246	In Vitro Senescence and Apoptotic Cell Death of Human Megakaryocytes. <i>Blood</i> , 1997, 90, 2234-2243.	0.6	14
247	Changes of Nuclear Protein Kinase C Activity and Isotype Composition in PC12 Cell Proliferation and Differentiation. <i>Experimental Cell Research</i> , 1996, 224, 72-78.	1.2	59
248	DIFFERENTIAL REGULATION OF BCL-2 AND C-FOS GENES BY HIV-1 TAT PROTEIN IN SERUM-STARVED AND ACTIVATED LYMPHOID T CELLS. <i>Biochemical Society Transactions</i> , 1996, 24, 593S-593S.	1.6	0
249	PMA-induced megakaryocytic differentiation of HEL cells is accompanied by striking modifications of protein kinase C catalytic activity and isoform composition at the nuclear level. <i>British Journal of Haematology</i> , 1996, 92, 530-536.	1.2	34
250	Impaired survival of bone marrow GPIIb/IIIa + megakaryocytic cells as an additional pathogenetic mechanism of HIV-related thrombocytopenia. <i>British Journal of Haematology</i> , 1996, 92, 711-717.	1.2	53
251	Nuclear translocation of protein kinase C-alpha and -zeta isoforms in HL-60 cells induced to differentiate along the granulocytic lineage by all-trans retinoic acid. <i>British Journal of Haematology</i> , 1996, 93, 542-550.	1.2	61
252	The Human Immunodeficiency Virus Type-1 (HIV-1) Tat Protein and Bcl-2 Gene Expression. <i>Leukemia and Lymphoma</i> , 1996, 23, 551-560.	0.6	35

#	ARTICLE	IF	CITATIONS
253	Extracellular Human Immunodeficiency Virus Type-1 Tat Protein Activates Phosphatidylinositol 3-Kinase in PC12 Neuronal Cells. <i>Journal of Biological Chemistry</i> , 1996, 271, 22961-22964.	1.6	65
254	An Autocrine Loop of HIV Type-1 Tat Protein Responsible for the Improved Survival/Proliferation Capacity of Permanently Tat-Transfected Cells and Required for Optimal HIV-1 LTR Transactivating Activity. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1995, 10, 306-316.	0.3	36
255	Tat-expressing Jurkat cells show an increased resistance to different apoptotic stimuli, including acute human immunodeficiency virus-type 1 (HIV -1) infection. <i>British Journal of Haematology</i> , 1995, 89, 24-33.	1.2	50
256	The CD4 receptor plays essential but distinct roles in HIV-1 infection and induction of apoptosis in primary bone marrow GPIIb/IIIa <sup>+</sup> megakaryocytes and the HEL cell line. <i>British Journal of Haematology</i> , 1995, 91, 290-298.	1.2	17
257	5 Effect of human immunodeficiency virus infection on haematopoiesis. <i>Best Practice and Research: Clinical Haematology</i> , 1995, 8, 113-130.	1.1	46
258	Human megakaryocyte biology and pathophysiology. <i>Critical Reviews in Oncology/Hematology</i> , 1995, 21, 135-157.	2.0	19
259	Tiazofurin Induces a Down-Modulation of ICAM-1 Expression on K562 Target Cells Impairing NK Adhesion and Killing. <i>Cellular Immunology</i> , 1995, 164, 100-104.	1.4	15
260	HIV Type 1 Extracellular Tat Protein Stimulates Growth and Protects Cells of BK Virus-Transgenic Mice from Apoptosis. <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 1039-1048.	0.5	58
261	All-Trans Retinoic Acid and Induction of Apoptosis in Acute Promyelocytic Leukemia Cells. <i>Leukemia and Lymphoma</i> , 1994, 14, 503-507.	0.6	22
262	Recombinant human immunodeficiency virus type-1 (HIV-1) Tat protein sequentially up-regulates IL-6 and TGF- $\beta$ 1 mRNA expression and protein synthesis in peripheral blood monocytes. <i>British Journal of Haematology</i> , 1994, 88, 261-267.	1.2	76
263	Increased serum levels of transforming growth factor $\beta$ -1 in patients affected by thrombotic thrombocytopenic purpura (TTP): its implications on bone marrow haematopoiesis. <i>British Journal of Haematology</i> , 1993, 84, 381-386.	1.2	21
264	Reduced responsiveness of bone marrow megakaryocyte progenitors to platelet-derived transforming growth factor $\beta$ 1, produced in normal amount, in patients with essential thrombocythaemia. <i>British Journal of Haematology</i> , 1993, 83, 14-20.	1.2	42
265	Role of HIV infection in the hematologic manifestations of HIV seropositive subjects. <i>Critical Reviews in Oncology/Hematology</i> , 1993, 15, 271-283.	2.0	20
266	Uninfected haematopoietic progenitor (CD34 <sup>+</sup> ) cells purified from the bone marrow of AIDS patients are committed to apoptotic cell death in culture. <i>Aids</i> , 1993, 7, 1049-1056.	1.0	61
267	Effect of different human immunodeficiency virus type-1 (HIV-1) isolates on long-term bone marrow haemopoiesis. <i>British Journal of Haematology</i> , 1993, 85, 596-602.	1.2	34
268	Progressive and Selective Impairment of IL-3 and IL-4 Production by Peripheral Blood CD4 <sup>+</sup> T-Lymphocytes During the Course of HIV-1 Infection. <i>Viral Immunology</i> , 1992, 5, 185-194.	0.6	17
269	Lack of compensatory megakaryocytopoiesis in HIV-1-seropositive thrombocytopenic individuals compared with immune thrombocytopenic purpura patients. <i>Aids</i> , 1991, 5, 1345-1350.	1.0	19
270	Essential thrombocythemia: Impaired regulation of megakaryocyte progenitors. <i>International Journal of Cell Cloning</i> , 1991, 9, 43-56.	1.6	23



#	ARTICLE	IF	CITATIONS
271	Impaired GM-CSF production by cultured light density mononuclear cells and T lymphocytes correlates with the number of circulating CFU-gm in HTV-1 seropositive subjects. International Journal of Cell Cloning, 1991, 9, 239-250.	1.6	17
272	In vivo and in vitro inhibitory effect of $\hat{I}\pm$ -interferon on megakaryocyte colony growth in essential thrombocythaemia. British Journal of Haematology, 1989, 71, 177-181.	1.2	76
273	In vivo and in vitro production of haemopoietic colony-stimulating activity by murine cell lines of different origin: a frequent finding. European Journal of Cancer & Clinical Oncology, 1989, 25, 1281-1286.	0.9	16